Formation Of Antibodies And Subsequent Prediction Of Clinical Response In Patients With Rheumatoid Arthritis Treated With Four Tnf Blocking Agents

Trial Profile

Formation Of Antibodies And Subsequent Prediction Of Clinical Response In Patients With Rheumatoid Arthritis Treated With Four Tnf Blocking Agents

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 03 Jan 2017

At a glance

  • Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Mar 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Dec 2014 Planned End Date changed from 1 Feb 2015 to 1 Mar 2015 according to ClinicalTrials.gov record.
    • 14 May 2013 Planned End Date changed from 1 Oct 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top